AQST Aquestive Therapeutics, Inc.: institutional ownership and insider trading
190 funds reported holding $344M of Aquestive Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $24.5M, with 27 new positions and 18 funds selling out; over the last 12 months insiders bought $0 and sold $2.39M on the open market; over its last four quarters it reported revenue of $54.1M and net income of −$78.2M.
AQST revenue and earnings
- Quarter ended Jun 30, 2026: revenue $13.8M, net income −$22.9M, EPS -0.18
- Quarter ended Mar 31, 2026: revenue $14.4M, net income −$8.06M, EPS -0.07
- Quarter ended Dec 31, 2025: revenue $13.0M, net income −$31.9M, EPS -0.26
- Quarter ended Sep 30, 2025: revenue $12.8M, net income −$15.4M, EPS -0.14
Famous investors holding AQST
- Two Sigma (Two Sigma Investments): $5.33M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $2.96M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.73M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $157K, 0.0% of the portfolio
Largest institutional holders of AQST
- Bratton Capital Management, L.P. — $40.8M
- VANGUARD GROUP INC — $38.1M
- BlackRock, Inc. (BLK) — $33.6M
- RTW INVESTMENTS, LP — $30.9M
- VANGUARD CAPITAL MANAGEMENT LLC — $19.1M
- FEDERATED HERMES, INC. (FHI) — $12.9M
- STATE STREET CORP (STT, STT-PG) — $12.2M
- GEODE CAPITAL MANAGEMENT, LLC — $10.9M
- Samsara BioCapital, LLC — $10.4M
- BANK OF AMERICA CORP /DE/ (BAC, BAC-PB, BAC-PE, BAC-PK, BAC-PL, BAC-PM, BAC-PN, BAC-PO, BAC-PP, BML-PG, BML-PH, BML-PJ, BML-PL) — $6.94M
Recent AQST insider trades
- Oct 15, 2026: Barber Daniel sold 25,000 shares ($106K)
- Sep 15, 2026: Barber Daniel sold 25,000 shares ($121K)
- Sep 9, 2026: Korczynski Sherry sold 8,750 shares ($45.7K)
- Aug 17, 2026: Barber Daniel sold 25,000 shares ($107K)
5%+ owners
- Bass Edward P: 7.5% (Schedule 13G, filed Oct 7, 2026)
- BlackRock, Inc.: 6.4% (Schedule 13G/A, filed Jul 27, 2026)
Who owns the most AQST stock?
The largest institutional holders of Aquestive Therapeutics, Inc. in the latest 13F filings are Bratton Capital Management, L.P. ($40.8M), VANGUARD GROUP INC ($38.1M), BlackRock, Inc. (BLK) ($33.6M).
Are insiders buying or selling AQST?
Over the last 12 months insiders bought $0 and sold $2.39M of Aquestive Therapeutics, Inc. stock on the open market (SEC Form 4).
Which famous investors own AQST?
Two Sigma, Ken Griffin, Renaissance Technologies, D. E. Shaw.
What was AQST's revenue last quarter?
Aquestive Therapeutics, Inc. reported revenue of $13.8M for the quarter ended June 30, 2026, with net income of −$22.9M.
Which ETFs hold AQST?
6 ETFs and mutual funds hold it among their top 100 positions, including XPH, WAMCX, WGICX, SURI.